A Phase II Study Of Topical Ceramide Lipids As Treatment For Cutaneous Breast Cancer
OBJECTIVES: I. Determine the objective response rate in women with cutaneous breast cancer
treated with topical ceramide cream. II. Determine the time to progression in patients
treated with this regimen. III. Determine the toxicity of this regimen in these patients.
IV. Assess the quality of life of these patients treated with this regimen.
OUTLINE: Topical ceramide cream is applied to all cutaneous lesions twice daily. Courses
repeat every 28 days in the absence of disease progression or unacceptable toxicity. Quality
of life is assessed at baseline and then at 1 and 3 months. Patients are followed every 3
months for 1 year and then every 6 months for 4 years.
PROJECTED ACCRUAL: A total of 22 patients will be accrued for this study within 27 months.
Primary Purpose: Treatment
Aminah Jatoi, MD
United States: Federal Government
|Mayo Clinic Cancer Center||Rochester, Minnesota 55905|
|CCOP - Wichita||Wichita, Kansas 67214-3882|
|CCOP - Missouri Valley Cancer Consortium||Omaha, Nebraska 68131|
|CCOP - Carle Cancer Center||Urbana, Illinois 61801|
|CCOP - Iowa Oncology Research Association||Des Moines, Iowa 50309-1016|
|CCOP - Scottsdale Oncology Program||Scottsdale, Arizona 85259-5404|
|CCOP - Cedar Rapids Oncology Project||Cedar Rapids, Iowa 52403-1206|
|Siouxland Hematology-Oncology||Sioux City, Iowa 51101-1733|
|CCOP - Merit Care Hospital||Fargo, North Dakota 58122|
|CCOP - Toledo Community Hospital Oncology Program||Toledo, Ohio 43623-3456|
|Rapid City Regional Hospital||Rapid City, South Dakota 57709|
|CCOP - Sioux Community Cancer Consortium||Sioux Falls, South Dakota 57105-1080|
|Medcenter One Health System||Bismarck, North Dakota 58501|